Women who have an increased risk of osteoporotic fractures will be able to get a new treatment on the NHS.
The NICE issued its final recommendation on denosumab, saying it was “good news” for post menopausal women in osteoporosis.
The treatment is given as an injection and mimics the body’s system of controlling the breakdown of bones.
Marketed under the trade name Prolia, denosumab targets cells that break down bones. This in turn increases bone density and reduces the risk of fracture.
Dr Carole Longson, health technology evaluation centre director at NICE, said: “We are pleased to be able to recommend denosumab to help prevent osteoporotic fractures in post-menopausal women at increased risk of fracture who are unable to take oral bisphosphonates.
“Denosumab joins the range of treatments that NICE has already advised should be available on the NHS, to help stop a fracture from occurring in the first place, or to help women who have previously had a fracture.
“This new guidance is good news for post-menopausal women at increased risk of fracture as it means that they now have a further treatment option to help them avoid suffering an osteoporotic fracture.”